CELESTIAL-RRMCL trial: what clinicians have said so far
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
- NCT06742996 ↗
- Recruiting
- BeOne Medicines
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on CELESTIAL-RRMCL (sonrotoclax plus zanubrutinib in relapsed/refractory mantle cell lymphoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Some of the questions raised in the 8 indexed sources
Automated from all 8 indexed sources (Jun 2025 – Oct 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice.
- Whether sonrotoclax with an anti-CD20 antibody improves on venetoclax-rituximab in relapsed CLL
- Whether obinutuzumab or rituximab is the more suitable antibody partner for sonrotoclax in relapsed CLL
- Whether stopping sonrotoclax in MRD-negative patients after induction can replace continued fixed-duration treatment
Indexed commentary on CELESTIAL-RRMCL so far
Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 5 posts on X, typically up to 22 once built | |
| 2 YouTube videos, typically up to 9 once built | |
| 1 podcast episode, typically up to 4 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Mantle Cell Lymphoma; B Cell Lymphoma
- Interventions
- Sonrotoclax; Zanubrutinib; Placebo
- Arms
- Arm A: sonrotoclax plus zanubrutinib · Experimental
- Arm B: placebo plus zanubrutinib · Placebo comparator
- Enrollment
- 300 (estimated)
- Primary outcomes
- Progression-Free Survival (PFS) as assessed by Blinded Independent Review Committee (BIRC)
- Sponsor
- BeOne Medicines
- Start
- Mar 5, 2025
- Primary completion
- Aug 31, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT06742996 · updated Oct 29, 2026